We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

93 hedge funds and large institutions have $147M invested in Akebia Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

2% more funds holding

Funds holding: 91 → 93 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

22% less capital invested

Capital invested by funds: $189M → $147M (-$41.9M)

41% less call options, than puts

Call options by funds: $1.94M | Put options by funds: $3.29M

Holders
93
Holders Change
+2
Holders Change %
+2.2%
% of All Funds
2.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
38
Reduced
27
Closed
12
Calls
$1.94M
Puts
$3.29M
Net Calls
-$1.35M
Net Calls Change
-$1.73M

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$5.43M
2
NCM
Nantahala Capital Management
Connecticut
+$2.91M
3
ACP
Acuta Capital Partners
California
+$1.87M
4
TC
TFS Capital
Pennsylvania
+$1.51M
5
BFA
BlackRock Fund Advisors
California
+$934K

Top Sellers

1
VAM
Visium Asset Management
New York
-$12.1M
2
Bank of America
Bank of America
North Carolina
-$4.77M
3
Stifel Financial
Stifel Financial
Missouri
-$4.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.62M
5
EAM
Eagle Asset Management
Florida
-$2.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Eagle Asset Management
Florida
$26.8M -$2.08M -238,064 -6%
First Manhattan
2
First Manhattan
New York
$13.9M -$10.5K -1,200 -0.1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$12.6M -$2.62M -300,400 -15%
NCM
4
Nantahala Capital Management
Connecticut
$12.6M +$2.91M +333,064 +25%
BFA
5
BlackRock Fund Advisors
California
$10.5M +$934K +107,049 +8%
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.12M +$587K +67,246 +7%
PA
7
Perceptive Advisors
New York
$6.68M +$250K +28,600 +3%
BIT
8
BlackRock Institutional Trust
California
$5.8M +$43.8K +5,020 +0.7%
ACA
9
Avoro Capital Advisors
New York
$4.65M +$5.43M +621,873 New
ACP
10
Acuta Capital Partners
California
$4.49M +$1.87M +213,692 +55%
Bank of America
11
Bank of America
North Carolina
$4.07M -$4.77M -546,218 -50%
State Street
12
State Street
Massachusetts
$3.63M +$555K +63,562 +15%
Marshall Wace
13
Marshall Wace
United Kingdom
$3.45M +$60.3K +6,911 +2%
Northern Trust
14
Northern Trust
Illinois
$2.78M +$480K +54,955 +17%
FO
15
FT Options
Illinois
$2.75M -$198K -22,643 -6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.71M +$68K +7,790 +4%
Morgan Stanley
17
Morgan Stanley
New York
$1.66M -$107K -12,243 -5%
EAM
18
EverPoint Asset Management
Connecticut
$1.5M -$1.31M -150,000 -43%
TC
19
TFS Capital
Pennsylvania
$1.3M +$1.51M +173,312 New
BIM
20
BlackRock Investment Management
Delaware
$1.08M +$120K +13,708 +10%
Wellington Management Group
21
Wellington Management Group
Massachusetts
$1.07M -$18.1K -2,070 -1%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$971K +$87.1K +9,982 +8%
LCM
23
Landscape Capital Management
New Jersey
$915K -$23.4K -2,675 -2%
TCIM
24
TIAA CREF Investment Management
New York
$835K +$171K +19,550 +21%
Charles Schwab
25
Charles Schwab
California
$789K +$15.4K +1,764 +2%
1
2 3 4 5

AKBA Hedge Fund Activity: Q2 2016 in Review

93 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2016, worth a combined $147M — down 22% from $189M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AKBA positions and 12 closed out — a net gain of 2 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $5.43M. The largest seller was Visium Asset Management, cutting an estimated $12.1M.

  • 93 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2016, up from 91 in Q1 2016.
  • Funds reported $147M of Akebia Therapeutics stock for Q2 2016, down 22% quarter-over-quarter.
  • 14 funds opened new Akebia Therapeutics positions in Q2 2016 and 12 closed out, a net change of +2 holders.
  • The largest Akebia Therapeutics buyer in Q2 2016 was Avoro Capital Advisors, an estimated $5.43M added.
  • The largest Akebia Therapeutics seller in Q2 2016 was Visium Asset Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2016.